XML 12 R4.htm IDEA: XBRL DOCUMENT v3.22.1
CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY
$ in Thousands
USD ($)
shares
₪ / shares
Ordinary shares
Ordinary shares - Class A
USD ($)
shares
Ordinary shares
Ordinary shares - Class B
USD ($)
shares
Preferred shares
USD ($)
shares
Receivables on account of shares
USD ($)
Additional Paid-in Capital
USD ($)
Accumulated Deficit
USD ($)
Balance at beginning of period (in shares) at Dec. 31, 2018 | shares     26,200,558 0 96,015,577      
Balance at beginning of period at Dec. 31, 2018 $ 13,332   $ 0 $ 0 $ 0 $ (89) $ 42,691 $ (29,270)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Received on account of shares 89         89    
Issuance of shares (in shares) | shares         7,296,925      
Issuance of shares, net 18,680           18,680  
Exercise of options (in shares) | shares     4,852,388          
Exercise of options 305           305  
Conversion of ordinary shares (in shares) | shares     (2,783,622)   2,783,622      
Conversion of preferred shares (in shares) | shares     11,803,687   (11,803,687)      
Conversion of convertible loan (in shares) | shares         878,191      
Conversion of convertible loan 2,353           2,353  
Recognition of beneficial ownership feature on convertible loan 355           355  
Extinguishment of beneficial conversion feature on convertible loan (2,353)           (2,353)  
Share-based compensation 7,046           7,046  
Net loss (12,195)             (12,195)
Balance at end of period (in shares) at Dec. 31, 2019 | shares     40,073,011 0 95,170,628      
Balance at end of period at Dec. 31, 2019 27,612   $ 0 $ 0 $ 0 0 69,077 (41,465)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuance of shares (in shares) | shares         9,638,101      
Issuance of shares, net $ 25,825           25,825  
Exercise of options (in shares) | shares 5,198,548   5,198,548          
Exercise of options $ 209           209  
Exercise of warrants (in shares) | shares         25,990,711      
Exercise of warrants 7,085           7,085  
Share-based compensation 52,763           52,763  
Net loss (67,713)             (67,713)
Balance at end of period (in shares) at Dec. 31, 2020 | shares     45,271,559 0 130,799,440      
Balance at end of period at Dec. 31, 2020 $ 45,781   $ 0 $ 0 $ 0 0 154,959 (109,178)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Common stock par value (in NIS per share) | ₪ / shares   ₪ 0.01            
Issuance of shares (in shares) | shares     2,610,101 83,417,110        
Exercise of options (in shares) | shares 3,715,925   3,715,925          
Exercise of options $ 809           809  
Exercise of warrants (in shares) | shares         10,662,377      
Exercise of warrants 2,907           2,907  
Conversion of preferred shares (in shares) | shares     141,461,817   (141,461,817)      
PIPE and merger financing (in shares) | shares     41,203,234          
SPAC merger and PIPE financing 258,159           258,159  
Share-based compensation 448,077           448,077  
Net loss (505,330)             (505,330)
Balance at end of period (in shares) at Dec. 31, 2021 | shares     234,262,636 83,417,110 0      
Balance at end of period at Dec. 31, 2021 $ 250,403   $ 0 $ 0 $ 0 $ 0 $ 864,911 $ (614,508)